New diabetes treatment lowers blood sugar with less need for insulin

Feb 16, 2011 By Erin McColgan

Diabetes can result from either a deficiency of insulin (type 1 or insulin-dependent diabetes) or decreased sensitivity to insulin (type 2 diabetes). Researchers at Children's Hospital Boston have discovered a mechanism for normalizing blood sugar that doesn't involve insulin and could offer a new therapeutic approach to both kinds of diabetes.

Reporting in online on February 13, Umut Ozcan, MD, and colleagues in Children's Division of Endocrinology show that a regulatory protein called XBP-1s, when activated artificially in the liver, can normalize in both lean, insulin-deficient type 1 diabetic mice and obese, insulin-resistant type 2 diabetic mice. This suggests that approaches aimed at increasing XBP-1s activity may benefit patients with either type of diabetes.

In previous work, Ozcan's lab identified XBP-1s as a key to the body's sensitivity to insulin, and shown that its function is impaired in the presence of obesity. Initially, XBP-1s was thought to increase and normalize blood glucose by binding to DNA and relieving stress on the endoplasmic reticulum, a cellular organ that assembles and folds proteins. When XBP-1s was artificially activated, "blood sugars in obese mice with came down abruptly," Ozcan says.

In the new study, Ozcan and colleagues show that XBP-1s regulates blood sugar in a second way: It causes the degradation of a protein, FoxO1, whose actions include increasing glucose output from the liver and stimulating feeding behavior in the brain. This degradation of FoxO1, the researchers show, is independent of XBP-1s' effect on the insulin signaling system, and by itself leads to a reduction in and increased (more rapid clearing of glucose from the blood).

"Activating XBP-1s could be another approach to type 2 diabetes, and could be very beneficial for , too," says Ozcan. "Even in mice with no insulin, increased expression of XBP-1s lowered the blood glucose level significantly. This suggests that approaches that activate XBP-1s in the liver of type 1 diabetics could control blood glucose levels, with potentially much less requirement for insulin."

Ozcan's lab is now seeking practical ways to activate XBP-1s that would lend themselves to clinical development. Currently the only treatment for type 1 diabetes is insulin, which requires injections and requires close monitoring to avoid hypoglycemia. Drugs are available for type 2 diabetes, but it remains difficult to control.

Explore further: Artificial sweeteners linked to abnormal glucose metabolism

add to favorites email to friend print save as pdf

Related Stories

A new strategy normalizes blood sugars in diabetes

Mar 28, 2010

Researchers at Children's Hospital Boston have identified a new strategy for treating type 2 diabetes, identifying a cellular pathway that fails when people become obese. By activating this pathway artificially, they were ...

Bypassing the insulin highway

Apr 28, 2008

An immune cell known as a neutrophil releases a protein that can suppress glucose production in the liver –without targeting insulin, researchers have found.

Apelin hormone injections powerfully lower blood sugar

Nov 04, 2008

By injecting a hormone produced by fat and other tissues into mice, researchers report in the November Cell Metabolism that they significantly lowered blood sugar levels in normal and obese mice. The findings suggest that t ...

Exercise pivotal in preventing and fighting type II diabetes

Feb 07, 2007

One in three American children born in 2000 will develop type II diabetes, according to the U.S. Centers for Disease Control and Prevention (CDC). A new study at the University of Missouri-Columbia says that acute exercise ...

Recommended for you

Connection found between birth size and brain disorders

15 hours ago

(Medical Xpress)—A trio of researchers has found what appears to be a clear connection between birth size and weight, and the two brain disorders, autism and schizophrenia. In their paper published in Proceedings of ...

A novel therapy for sepsis?

Sep 16, 2014

A University of Tokyo research group has discovered that pentatraxin 3 (PTX3), a protein that helps the innate immune system target invaders such as bacteria and viruses, can reduce mortality of mice suffering ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

panna
not rated yet Feb 17, 2011
the article shows a novel and potencially beneficial way of treatment of perhaps any type of diabetes.it will provide a new and effective insight into treatment of the disease.